SMLR vs. CDRE, PLSE, LQDA, RXST, INMD, AORT, MDXG, BLFS, FNA, and EMBC
Should you be buying Semler Scientific stock or one of its competitors? The main competitors of Semler Scientific include Cadre (CDRE), Pulse Biosciences (PLSE), Liquidia (LQDA), RxSight (RXST), InMode (INMD), Artivion (AORT), MiMedx Group (MDXG), BioLife Solutions (BLFS), Paragon 28 (FNA), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.
Semler Scientific vs.
Semler Scientific (NASDAQ:SMLR) and Cadre (NYSE:CDRE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Semler Scientific has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
In the previous week, Cadre had 2 more articles in the media than Semler Scientific. MarketBeat recorded 4 mentions for Cadre and 2 mentions for Semler Scientific. Cadre's average media sentiment score of 0.81 beat Semler Scientific's score of 0.28 indicating that Cadre is being referred to more favorably in the news media.
Cadre received 14 more outperform votes than Semler Scientific when rated by MarketBeat users. However, 66.67% of users gave Semler Scientific an outperform vote while only 55.17% of users gave Cadre an outperform vote.
49.4% of Semler Scientific shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 30.2% of Semler Scientific shares are owned by company insiders. Comparatively, 37.0% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Semler Scientific currently has a consensus target price of $71.00, suggesting a potential upside of 48.88%. Cadre has a consensus target price of $39.75, suggesting a potential upside of 11.63%. Given Semler Scientific's stronger consensus rating and higher probable upside, research analysts plainly believe Semler Scientific is more favorable than Cadre.
Semler Scientific has a net margin of 27.00% compared to Cadre's net margin of 6.34%. Semler Scientific's return on equity of 20.31% beat Cadre's return on equity.
Cadre has higher revenue and earnings than Semler Scientific. Semler Scientific is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
Summary
Semler Scientific and Cadre tied by winning 9 of the 18 factors compared between the two stocks.
Get Semler Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMLR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Semler Scientific Competitors List
Related Companies and Tools
This page (NASDAQ:SMLR) was last updated on 2/13/2025 by MarketBeat.com Staff